Home > Insider Trading > Filing (0001476860-10-000008)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885590	Valeant Pharmaceuticals International Inc.	VRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1476860	Mcdowall William Wells	C/O 7150 Mississauga Road Mississauga A6 L5N 8M5		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, No Par Value	Disposition	2010-12-06	490,461	$28.13	75,000	No	4	S	Direct
Common Stock, No Par Value	Acquisiton	2010-12-07	19,540	$0.00	94,540	No	4	M	Direct
Common Stock, No Par Value	Disposition	2010-12-07	2,150	$26.12	92,390	No	4	F	Direct
Common Stock, No Par Value	Disposition	2010-12-07	17,390	$28.05	75,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, No Par Value	Restricted Share Units	Disposition	2010-12-07	19,540	$0.00	19,540	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2010-11-08	2013-02-17	No	4	M	Direct

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.29, inclusive. The reporting person undertakes to provide to Valeant Pharmaceuticals International, Inc. ("Valeant"), any shareholder of Valeant, or the staff of the Securities and Exchange Commission, in each case upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of Restricted Stock Units ("RSUs").
Each RSU represents a contingent right to receive one common share, no par value, of Valeant.
The RSUs accelerated in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010.